Search research publications and outputs

  1. 1991
  2. 1992
  3. 1993
  4. 1994
  5. 1995
  6. 1996
  7. 1998
  8. 1999
  9. 2001
  10. 2002
  11. 2003
  12. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis

    Cooper, N. J., Claxton, K., Chilcott, J., McCabe, C., Tappenden, P., O'Hagan, A. & Abrams, K., 8 Mar 2003

    Article in BMJ

  13. Density functionals, with an option-pricing application

    Abadir, K. M. & Rockinger, M., Oct 2003

    Article in Econometric Theory

  14. 2004
  15. 2005
  16. Orphan drugs and the NHS: Should we value rarity

    Claxton, K., McCabe, C. & Tsuchiya, A., 29 Oct 2005

    Article in BMJ

  17. 2006
  18. 2007
  19. 2008
  20. Welfarism vs. extra-welfarism

    Brouwer, W. B. F., Culyer, A. J., van Exel, N. J. A. & Rutten, F. F. H., Mar 2008

    Article in Journal of health economics

  21. 2009
  22. 2010
  23. 2012
  24. 2013
  25. 2014
  26. 2015
  27. 2016
  28. International Society for Pharmacoeconomics and Outcomes Research Comments on the American Society of Clinical Oncology Value Framework

    Malone, D. C., Berg, N. S., Claxton, K., Garrison, L. P., IJzerman, M., Marsh, K., Neumann, P. J., Sculpher, M., Towse, A., Uyl-de Groot, C. & Weinstein, M. C., 13 Jun 2016

    Article in Journal of Clinical Oncology

  29. Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal

    Morton, A., Adler, A. I., Bell, D., Briggs, A., Brouwer, W., Claxton, K., Craig, N., Fischer, A., McGregor, P. & van Baal, P., Aug 2016

    Article in Health Economics

  30. Cancer Drugs Fund requires further reform: Reliance on “real world” observational data undermines evidence base for clinical practice

    Grieve, R., Abrams, K., Claxton, K. P., Goldacre, B., James, N., Nicholl, J., Parmar, M., Parker, C., Sekhon, J. S., Smeeth, L., Spiegelhalter, D. & Sculpher, M. J., 27 Sep 2016

    Article in British medical journal

Previous 1 2 3 Next